SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Tricida, Inc. today announced that its management will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 in San Francisco, California. The presentation is scheduled for 3:30 pm PT.
Tricida, Inc. is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies. Tricida’s lead investigational drug candidate, TRC101, represents a first-in-class approach to the treatment of metabolic acidosis, a common complication of chronic kidney disease (CKD) that can result in increased mortality, accelerated progression of kidney disease, progressive muscle breakdown and exacerbation of bone disease. TRC101 is a non-absorbed, orally-administered polymer, designed to remove acid from the body with high capacity and specificity, with the objective to treat chronic metabolic acidosis associated with CKD as measured by an increase of patients’ serum bicarbonate levels.
For more information, visit www.tricida.com.